C12N 2310/34
Spatial arrangement of the modifications
C12N2310/34 (Spatial arrangement of the modifications) appears on 2,040 US grants and 4,098 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,040
- Published applications
- 4,098
- Assignees
- 765
- Inventors
- 3,725
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 9 | 0 |
| 1999 | 47 | 0 |
| 2000 | 76 | 0 |
| 2001 | 59 | 9 |
| 2002 | 67 | 35 |
| 2003 | 36 | 219 |
| 2004 | 27 | 258 |
| 2005 | 23 | 164 |
| 2006 | 16 | 72 |
| 2007 | 19 | 78 |
| 2008 | 18 | 41 |
| 2009 | 23 | 84 |
| 2010 | 55 | 80 |
| 2011 | 47 | 82 |
| 2012 | 61 | 86 |
| 2013 | 65 | 99 |
| 2014 | 75 | 128 |
| 2015 | 86 | 153 |
| 2016 | 91 | 173 |
| 2017 | 111 | 152 |
| 2018 | 110 | 188 |
| 2019 | 111 | 185 |
| 2020 | 111 | 205 |
| 2021 | 119 | 241 |
| 2022 | 140 | 285 |
| 2023 | 106 | 287 |
| 2024 | 118 | 312 |
| 2025 | 130 | 278 |
| 2026 | 72 | 204 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2310/346Having a combination of backbone and sugar modificationsIndexing code1,344
- C12N 2310/341Gapmers, i.e. of the type ===---===Indexing code1,060
- C12N 2310/344Position-specific modificationsIndexing code414
- C12N 2310/343Having patternsIndexing code222
- C12N 2310/345Having at least two different backbone modificationsIndexing code192
- C12N 2310/342Hemimers, i.e. of the type ====----Indexing code18
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- RNAi constructs and methods for inhibiting LPA expression22 Sep 2026US 12,742,169 B2Amgen Inc.
- Modified guide RNAs15 Sep 2026US 12,735,698 B2Intellia Therapeutics, Inc.
- Compounds and methods for reducing FUS expression15 Sep 2026US 12,735,700 B2Ionis Pharmaceuticals, Inc.
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Oligonucleotide compositions and methods thereof1 Oct 2026US 2026/0297573 A1Wave Life Sciences Ltd.
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Hybrid oligonucleotide phosphorothioates427US 5,652,355 AWorcester Foundation for Experimental Biology · 1997
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012